Effect of Off-Target Binding on 18F-Flortaucipir Variability in Healthy Controls Across the Life Span
暂无分享,去创建一个
William J. Jagust | Suzanne L. Baker | Renaud La Joie | Theresa M. Harrison | W. Jagust | A. Maass | S. Baker | R. La Joie | T. Harrison | Anne Maass
[1] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[2] W. Jagust,et al. Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data , 2017, Data in brief.
[3] Alan A. Wilson,et al. Distribution of Monoamine Oxidase Proteins in Human Brain: Implications for Brain Imaging Studies , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[4] N. Volkow,et al. Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[5] Clifford R. Jack,et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia , 2016, Acta Neuropathologica Communications.
[6] J. Barrio,et al. The Irony of PET Tau Probe Specificity , 2018, The Journal of Nuclear Medicine.
[7] Valerie Treyer,et al. Low cortical iron and high entorhinal cortex volume promote cognitive functioning in the oldest-old , 2017, Neurobiology of Aging.
[8] Min-Ying Su,et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. , 2013, Journal of Alzheimer's disease : JAD.
[9] Dietmar R. Thal,et al. Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.
[10] Daniel R. Schonhaut,et al. PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.
[11] Hanna Cho,et al. Off-Target 18F-AV-1451 Binding in the Basal Ganglia Correlates with Age-Related Iron Accumulation , 2018, The Journal of Nuclear Medicine.
[12] A. Joshi,et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. , 2016, Brain : a journal of neurology.
[13] Elizabeth C Mormino,et al. Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant , 2012, NeuroImage.
[14] Bradford C. Dickerson,et al. Tau PET imaging in aging and early Alzheimer's disease , 2015 .
[15] Charles DeCarli,et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. , 2015, Brain : a journal of neurology.
[16] A. Fagan,et al. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy. , 2016, JAMA neurology.
[17] B. Miller,et al. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders , 2018, JAMA.
[18] D. Brooks,et al. MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding , 2018, Molecular Imaging and Biology.
[19] M. Citron,et al. The tau positron‐emission tomography tracer AV‐1451 binds with similar affinities to tau fibrils and monoamine oxidases , 2018, Movement disorders : official journal of the Movement Disorder Society.
[20] Keith A. Johnson,et al. 18F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal. , 2018, Journal of Alzheimer's disease : JAD.
[21] M. Mintun,et al. Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease , 2016, The Journal of Nuclear Medicine.
[22] H. Kolb,et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.
[23] Nick C Fox,et al. Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias , 2016, Alzheimer's & Dementia.
[24] Keith A. Johnson,et al. Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.
[25] A. Evans,et al. Correction for partial volume effects in PET: principle and validation. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] Christopher G Schwarz,et al. Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. , 2018, Brain : a journal of neurology.
[27] N. Turro,et al. New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals , 2008, Proceedings of the National Academy of Sciences.
[28] M. Mintun,et al. Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity , 2017, The Journal of Nuclear Medicine.
[29] Rik Ossenkoppele,et al. Quantification of Tau Load Using [18F]AV1451 PET , 2017, Molecular Imaging and Biology.
[30] Keith A. Johnson,et al. Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson’s case , 2017, Acta Neuropathologica Communications.
[31] M. Bobinski,et al. Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.
[32] William J. Jagust,et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease , 2017, NeuroImage.
[33] Suzanne L Baker,et al. Reference Tissue–Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging , 2017, The Journal of Nuclear Medicine.
[34] M. Mintun,et al. Kinetic Modeling of the Tau PET Tracer 18F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects , 2017, The Journal of Nuclear Medicine.
[35] Brian A. Gordon,et al. Widespread distribution of tauopathy in preclinical Alzheimer's disease , 2018, Neurobiology of Aging.